Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lipoprotein(a) (Lp(a)) has been established as an important independent risk factor for the development of cardiovascular disease. Apolipoprotein(a), together with apo B-100 the apolipoprotein of Lp(a), is homologeous to plasminogen but lacks fibrinolytic capacity and appeared to interfere with fibrinolysis in in vitro and ex vivo experiments. We determined the correlations between Lp(a) and other blood lipids (serum cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides), coagulation parameters (fibrinogen, factor VII, factor VIII:C fibrin monomers, thrombin-antithrombin III) and fibrinolysis parameters (tissue plasminogen activator antigen, plasminogen activator inhibitor-1 and D-dimer) in 54 patients with essential hypertension, in 65 non-insulin-dependent diabetic patients and in 116 insulin-regulated diabetic patients. Signs of activated coagulation and increased reactive fibrinolysis were found in all three patient groups. In the hypertensive patients, Lp(a) was significantly correlated with LDL-cholesterol (r = 0.25, P = 0.04) and triglycerides (r = -0.30, P = 0.03), while in insulin-regulated diabetics, Lp(a) was also correlated with LDL-cholesterol (r = 0.20, P = 0.03). In the hypertensive patients and both diabetic groups there was no correlation of Lp(a) with coagulation or fibrinolysis parameters. These data show that Lp(a) concentrations are not related to coagulation or fibrinolysis parameters in hypertensive or diabetic patients and confirm the presence of an activated coagulation system in these patient groups.
 ...
PMID:Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients. 138 33

To observe the damage of vascular endothelium in vivo, we measured the circulating endothelial cell (CEC) with Hladovec's method in 30 patients with essential hypertension (EH) and 66 normal controls. The CEC was verified by direct immunofluorescent staining using anti-human factor VIII serum. The results showed that a significantly increased CEC count was found in patients with EH (3.018 +/- 1.230 vs 1.310 +/- 0.710, P less than 0.01), but the number of CEC was not parallel to the change of blood pressure quantitatively. After antihypertensive therapy, the CEC count reduced markedly in partial patients (3.371 +/- 0.770 vs 2.410 +/- 0.782, P less than 0.05). The study indicated that the damage of vascular endothelium indeed existed in EH, the abnormality can be improved by antihypertension. The CEC count was a simple and sensitive method for the demonstration of endothelial lesion in vivo.
 ...
PMID:[Changes in circulating endothelial cells in patients with essential hypertension]. 181 85